Subscribe to news

Press Center

12.03.2012
OJSC HSCI – The Human Stem Cells Institute ("HSCI", MICEX: ISKJ), one of Russia's leading biotech companies, has announced the results of the first two years following its IPO and presented an overview of the Company's strategy for 2012-2016.
07.12.2011
OJSC HSCI – The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), Russia’s biotech company, announced today that it has received state approval for Neovasculgen® – the first Russian gene-therapy drug to treat Peripheral Arterial Disease.
06.09.2011
OJSC HSCI – The Human Stem Cells Institute ("HSCI", MICEX:ISKJ), a Russian company engaged in the development, manufacturing and commercialization of products and services in the realm of cell-based, gene and post-genome technologies, announced today that its Extraordinary General Shareholders' Meeting has approved an Investment agreement for the SynBio project - the first ever international M&A in the global biotech sector initiated by a Russian company.
04.08.2011
OJSC HSCI – The Human Stem Cells Institute (MICEX: ISKJ), a Russian company engaged in the development, manufacturing and commercialization of products and services in the realm of cell-based, gene and post-genome technologies, today announces the parameters of the SynBio project.